Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

Ratios

vs
industry
vs
history
P/E(ttm) 20.92
FVD's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 20.92 )
Ranked among companies with meaningful P/E(ttm) only.
FVD' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.08
Current: 20.92
0
21.08
PE(NRI) 20.92
FVD's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 20.92 )
Ranked among companies with meaningful PE(NRI) only.
FVD' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.08
Current: 20.92
0
21.08
P/B 2.61
FVD's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.61 )
Ranked among companies with meaningful P/B only.
FVD' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.61
Current: 2.61
0
2.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.08
FVD's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.08 )
Ranked among companies with meaningful Dividend Yield only.
FVD' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.08
Current: 2.08
0
2.08
Yield on cost (5-Year) 2.08
FVD's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.08 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
FVD' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.08
Current: 2.08
0
2.08

More Statistics

Short Percentage of Float0.00%
52-Week Range $22.06 - 27.50
Shares Outstanding (Mil)87,937,986.00
» More Articles for FVD

Headlines

Articles On GuruFocus.com
Don’t Lose Your Money to Mobileye Aug 25 2016 
Tight Trading on Thursday with Stocks Ending Lower Aug 25 2016 
What to Expect from Microsoft Beyond 2016 Aug 25 2016 
Is MasterCard More Attractive than Visa at this Price Point? Aug 25 2016 
Why You Need Dividend Stocks in Your Portfolio Aug 25 2016 
Goldcorp Inc.: Contamination of Selenium at Penasquito Aug 25 2016 
An In-Depth Look at the VBI Vaccines CMV Study Aug 25 2016 
There’s More Than One Way to Find a Great Stock Aug 25 2016 
A Look at Four Stocks in Oakmark Small Cap International Aug 25 2016 
IBM’s Under-The-Radar Initiatives Aug 25 2016 

More From Other Websites
Litigation Has Teva Pharmaceutical’s Copaxone 40 mg All Tied Up Aug 24 2016
Why AstraZeneca Reported Negative Growth in 2Q16 Aug 23 2016
Is AstraZeneca’s Valuation Improving Compared to Peers? Aug 23 2016
This Changed Sanofi’s Profitability in 2Q16 Aug 23 2016
Inside the Performance of Sanofi’s Human Vaccines Segment in 2Q16 Aug 22 2016
What Are Analysts Recommending for Teva Pharmaceutical in 2016? Aug 19 2016
How Much Did Sanofi’s Established Prescription Products Affect Growth in 2Q16? Aug 19 2016
Kohl’s 2Q16 Sales Beat Estimates despite a Decline Aug 18 2016
Understanding Sanofi’s Growth Drivers in 2Q16 Aug 17 2016
Analysts’ Recommendations for Kellogg before Its 2Q16 Results Aug 01 2016
How Much Did Kellogg Return to Shareholders? Jul 29 2016
Why Analysts Think AstraZeneca’s Revenues Will Fall in 2Q16 Jul 26 2016
Newly Acquired Products Boost GlaxoSmithKline’s Earnings Jul 26 2016
What Do the Recent Changes in Novartis’s 2Q16 Valuation Tell Us? Jul 26 2016
How Do the Majority of Analysts Rate Novartis after 2Q16? Jul 25 2016
Will Anheuser-Busch InBev’s 2Q16 Revenue Rise? Jul 25 2016
GlaxoSmithKline Segments That Drive Company’s Rising Revenues Jul 22 2016
What Role Did Sandoz Play in Novartis’s 2Q16 Earnings? Jul 22 2016
Inside the Foreign Exchange Impact on Novartis’s Growth in 2Q16 Jul 21 2016
Top Funds Invest In Every U.S. Dividend Payer And Beat The Market Jul 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK